Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1022

1.

Sarcopenia is related to spinal sagittal imbalance in patients with spinopelvic mismatch.

Ohyama S, Hoshino M, Terai H, Toyoda H, Suzuki A, Takahashi S, Hayashi K, Tamai K, Hori Y, Nakamura H.

Eur Spine J. 2019 Jul 17. doi: 10.1007/s00586-019-06066-2. [Epub ahead of print]

PMID:
31317307
2.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019 Jul 15:1-9. doi: 10.1159/000501281. [Epub ahead of print]

PMID:
31307035
3.

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.

J Viral Hepat. 2019 Jul 6. doi: 10.1111/jvh.13170. [Epub ahead of print]

PMID:
31278795
4.

The mechanosensitive channel YbdG from Escherichia coli has a role in adaptation to osmotic up-shock.

Amemiya S, Toyoda H, Kimura M, Saito H, Kobayashi H, Ihara K, Kamagata K, Kawabata R, Kato S, Nakashimada Y, Furuta T, Hamamoto S, Uozumi N.

J Biol Chem. 2019 Jun 29. pii: jbc.RA118.007340. doi: 10.1074/jbc.RA118.007340. [Epub ahead of print]

5.

Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model.

Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.

J Med Virol. 2019 Oct;91(10):1837-1844. doi: 10.1002/jmv.25533. Epub 2019 Jul 16.

PMID:
31254403
6.

Increased advanced glycation end products in hypertrophied ligamentum flavum of diabetes mellitus patients.

Maruf MH, Suzuki A, Hayashi K, Habibi H, Salimi H, Terai H, Tamai K, Hoshino M, Toyoda H, Yamada K, Takahashi S, Ohyama S, Hori Y, Nakamura H.

Spine J. 2019 Jun 10. pii: S1529-9430(19)30795-8. doi: 10.1016/j.spinee.2019.06.001. [Epub ahead of print]

PMID:
31195134
7.

Clinical Impact of Cervical Imbalance on Surgical Outcomes of Laminoplasty: A Propensity Score-Matching Analysis.

Tamai K, Suzuki A, Yabu A, Terai H, Hoshino M, Toyoda H, Takahashi S, Ohyama S, Hori Y, Nakamura H.

Clin Spine Surg. 2019 May 31. doi: 10.1097/BSD.0000000000000849. [Epub ahead of print]

PMID:
31162189
8.

The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J.

J Gastroenterol. 2019 Jun 3. doi: 10.1007/s00535-019-01595-5. [Epub ahead of print]

PMID:
31161311
9.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

10.

Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.

Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T.

Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.

11.

Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease.

Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J.

J Gastroenterol Hepatol. 2019 May 21. doi: 10.1111/jgh.14734. [Epub ahead of print]

PMID:
31115065
12.

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH.

J Hepatol. 2019 May 13. pii: S0168-8278(19)30279-X. doi: 10.1016/j.jhep.2019.04.017. [Epub ahead of print]

PMID:
31096005
13.

Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.

Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.

Eur J Gastroenterol Hepatol. 2019 May 6. doi: 10.1097/MEG.0000000000001434. [Epub ahead of print]

PMID:
31082998
14.

Effects of Cu2+ on conformational change and aggregation of hPrP180-192 with a V180I mutation of the prion protein.

Sakaguchi Y, Nakamura R, Konishi M, Hatakawa Y, Toyoda H, Akizawa T.

Biochem Biophys Res Commun. 2019 Jun 30;514(3):798-802. doi: 10.1016/j.bbrc.2019.05.009. Epub 2019 May 10.

PMID:
31079927
15.

Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response.

Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T.

Clin Infect Dis. 2019 May 6. pii: ciz359. doi: 10.1093/cid/ciz359. [Epub ahead of print]

PMID:
31056696
16.

Fibroblast Growth Factor 9 Is Upregulated Upon Intervertebral Mechanical Stress-Induced Ligamentum Flavum Hypertrophy in a Rabbit Model.

Hayashi K, Suzuki A, Terai H, Ahmadi SA, Rahmani MS, Hasib MM, Habibi H, Hori Y, Yamada K, Hoshino M, Toyoda H, Takahashi S, Tamai K, Ohyama S, Imai Y, Nakamura H.

Spine (Phila Pa 1976). 2019 Apr 13. doi: 10.1097/BRS.0000000000003089. [Epub ahead of print]

PMID:
31022154
17.

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M.

Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.

18.

Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time.

Motoi S, Toyoda H, Obara T, Ohta E, Arita Y, Negishi K, Moriya K, Kuboi Y, Soejima M, Imai T, Ido A, Tsubouchi H, Kawano T.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1821. doi: 10.3390/ijms20081821.

19.

A numbering-up strategy of hydrodynamic microfluidic filters for continuous-flow high-throughput cell sorting.

Ozawa R, Iwadate H, Toyoda H, Yamada M, Seki M.

Lab Chip. 2019 May 14;19(10):1828-1837. doi: 10.1039/c9lc00053d.

PMID:
30998230
20.

Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios.

Tada T, Kumada T, Toyoda H, Yasuda S, Koyabu T, Nakashima M.

Nutr Cancer. 2019 Apr 6:1-10. doi: 10.1080/01635581.2019.1597905. [Epub ahead of print]

PMID:
30955354
21.

Direct-acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens.

Toyoda H.

Health Sci Rep. 2019 Mar 4;2(3):e106. doi: 10.1002/hsr2.106. eCollection 2019 Mar.

22.

Role of nicotinic acetylcholine receptors for modulation of microcircuits in the agranular insular cortex.

Toyoda H.

J Oral Biosci. 2019 Mar;61(1):5-11. doi: 10.1016/j.job.2018.12.001. Epub 2018 Dec 21. Review.

PMID:
30929802
23.

Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.

Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N.

Hepatol Res. 2019 Jul;49(7):810-822. doi: 10.1111/hepr.13338. Epub 2019 May 23.

PMID:
30920086
24.

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.

Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH.

Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398. doi: 10.1016/S2468-1253(19)30039-1. Epub 2019 Mar 20.

PMID:
30902670
25.

Aberration-resistible topological charge determination of annular-shaped optical vortex beams using Shack-Hartmann wavefront sensor.

Wang D, Huang H, Matsui Y, Tanaka H, Toyoda H, Inoue T, Liu H.

Opt Express. 2019 Mar 4;27(5):7803-7821. doi: 10.1364/OE.27.007803.

PMID:
30876337
26.

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.

Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14.

PMID:
30873651
27.

Establishment and characterization of Drosophila cell lines mutant for heparan sulfate modifying enzymes.

Nakato E, Liu X, Eriksson I, Yamamoto M, Kinoshita-Toyoda A, Toyoda H, Kjellén L, Li JP, Nakato H.

Glycobiology. 2019 Jun 1;29(6):479-489. doi: 10.1093/glycob/cwz020.

PMID:
30869121
28.

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8.

PMID:
30848363
29.

Answer to the Letter to the Editor concerning "The association of back muscle strength and sarcopenia-related parameters in the patients with spinal disorders" by Toyoda H, et al. (Eur Spine J; doi.org/10.1007/s00586-018-5858-8).

Toyoda H, Hoshino M, Ohyama S, Terai H, Suzuki A, Yamada K, Takahashi S, Hayashi K, Tamai K, Hori Y, Nakamura H.

Eur Spine J. 2019 May;28(5):1252-1253. doi: 10.1007/s00586-019-05942-1. Epub 2019 Mar 6. No abstract available.

PMID:
30840140
30.

Development of a scoring system for predicting adjacent vertebral fracture after balloon kyphoplasty.

Takahashi S, Hoshino M, Yasuda H, Hori Y, Ohyama S, Terai H, Hayashi K, Tsujio T, Kono H, Suzuki A, Tamai K, Toyoda H, Dohzono S, Sasaoka R, Kanematsu F, Nakamura H.

Spine J. 2019 Jul;19(7):1194-1201. doi: 10.1016/j.spinee.2019.02.013. Epub 2019 Mar 1.

PMID:
30831317
31.

Association between MRI findings and back pain after osteoporotic vertebral fractures: a multicenter prospective cohort study.

Ahmadi SA, Takahashi S, Hoshino M, Takayama K, Sasaoka R, Tsujio T, Yasuda H, Kanematsu F, Kono H, Toyoda H, Nakamura H.

Spine J. 2019 Jul;19(7):1186-1193. doi: 10.1016/j.spinee.2019.02.007. Epub 2019 Feb 14.

PMID:
30772505
32.

Interaction of nicotinic acetylcholine receptors with dopamine receptors in synaptic plasticity of the mouse insular cortex.

Toyoda H.

Synapse. 2019 Jul;73(7):e22094. doi: 10.1002/syn.22094. Epub 2019 Feb 18. Review.

PMID:
30767273
33.

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma.

Kariyama K, Nouso K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M, Group OBOTRPEFHRS, Group H.

Cancers (Basel). 2019 Feb 10;11(2). pii: E203. doi: 10.3390/cancers11020203.

34.

ISSLS PRIZE IN CLINICAL SCIENCE 2019: clinical importance of trunk muscle mass for low back pain, spinal balance, and quality of life-a multicenter cross-sectional study.

Hori Y, Hoshino M, Inage K, Miyagi M, Takahashi S, Ohyama S, Suzuki A, Tsujio T, Terai H, Dohzono S, Sasaoka R, Toyoda H, Kato M, Matsumura A, Namikawa T, Seki M, Yamada K, Habibi H, Salimi H, Yamashita M, Yamauchi T, Furuya T, Orita S, Maki S, Shiga Y, Inoue M, Inoue G, Fujimaki H, Murata K, Kawakubo A, Kabata D, Shintani A, Ohtori S, Takaso M, Nakamura H.

Eur Spine J. 2019 May;28(5):914-921. doi: 10.1007/s00586-019-05904-7. Epub 2019 Feb 6.

PMID:
30729293
35.

Experimentally induced rhythmic jaw muscle activities during non-rapid eye movement sleep in freely moving guinea pigs.

Yamada KI, Higashiyama M, Toyoda H, Masuda Y, Kogo M, Yoshida A, Kato T.

J Sleep Res. 2019 Jan 23:e12823. doi: 10.1111/jsr.12823. [Epub ahead of print]

PMID:
30675746
36.

CD3+ B-1a Cells as a Mediator of Disease Progression in Autoimmune-Prone Mice.

Yamamoto W, Toyoda H, Xu DQ, Hanaki R, Morimoto M, Nakato D, Ito T, Iwamoto S, Bonno M, Tanaka S, Hirayama M.

Mediators Inflamm. 2018 Dec 23;2018:9289417. doi: 10.1155/2018/9289417. eCollection 2018.

37.

Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection.

Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T.

Hepatol Res. 2019 May;49(5):512-520. doi: 10.1111/hepr.13311. Epub 2019 Feb 7.

PMID:
30628746
38.

Microdetermination of Sialic Acids in Blood Samples by Hydrophilic Interaction Chromatography Coupled to Post-column Derivatization and Fluorometric Detection.

Nagai Y, Sakakibara I, Toyoda H.

Anal Sci. 2019 May 10;35(5):517-520. doi: 10.2116/analsci.18P500. Epub 2018 Dec 28.

39.

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21.

40.

Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.

J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27.

PMID:
30549320
41.

The association of back muscle strength and sarcopenia-related parameters in the patients with spinal disorders.

Toyoda H, Hoshino M, Ohyama S, Terai H, Suzuki A, Yamada K, Takahashi S, Hayashi K, Tamai K, Hori Y, Nakamura H.

Eur Spine J. 2019 Feb;28(2):241-249. doi: 10.1007/s00586-018-5858-8. Epub 2018 Dec 12.

PMID:
30542935
42.

Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.

Takada A, Ii N, Hirayama M, Toyoda H, Matsubara T, Toyomasu Y, Kawamura T, Daimon T, Sakuma H, Nomoto Y.

J Neurosurg Pediatr. 2018 Nov 23;23(3):317-324. doi: 10.3171/2018.9.PEDS18181.

PMID:
30497152
43.

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K.

Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2.

PMID:
30485638
44.

Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction.

Tada T, Kumada T, Toyoda H, Kobayashi N, Sone Y, Oguri T, Kamiyama N.

AJR Am J Roentgenol. 2019 Feb;212(2):332-341. doi: 10.2214/AJR.18.20123. Epub 2018 Nov 26.

PMID:
30476453
45.

Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C.

Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.

Open Forum Infect Dis. 2018 Oct 22;5(11):ofy268. doi: 10.1093/ofid/ofy268. eCollection 2018 Nov.

46.

Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.

Kurihara K, Toyoda H, Amoano K, Inoue M, Uchida K, Sakurai H, Hayashi A, Hirayama M.

Pediatr Int. 2018 Nov;60(11):1039-1041. doi: 10.1111/ped.13697. Epub 2018 Oct 30. No abstract available.

PMID:
30375135
47.

The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.

Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, Tanaka J, Johnson PJ.

Liver Int. 2019 Mar;39(3):448-454. doi: 10.1111/liv.13987. Epub 2018 Nov 2.

PMID:
30312003
48.

Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study.

Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K.

Hepatol Res. 2019 Feb;49(2):125-135. doi: 10.1111/hepr.13256. Epub 2018 Nov 13.

PMID:
30307682
49.

Anatomical analysis of the human ligamentum flavum in the thoracic spine: Clinical implications for posterior thoracic spinal surgery.

Ahmadi SA, Suzuki A, Terai H, Tamai K, Akhgar J, Hoshino M, Toyoda H, Rahmani MS, Hayashi K, Ohyama S, Takahashi S, Nakamura H.

J Orthop Sci. 2019 Jan;24(1):62-67. doi: 10.1016/j.jos.2018.08.023. Epub 2018 Sep 29.

PMID:
30279134
50.

A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia.

Miyagawa T, Khor SS, Toyoda H, Kanbayashi T, Imanishi A, Sagawa Y, Kotorii N, Kotorii T, Ariyoshi Y, Hashizume Y, Ogi K, Hiejima H, Kamei Y, Hida A, Miyamoto M, Ikegami A, Wada Y, Takami M, Higashiyama Y, Miyake R, Kondo H, Fujimura Y, Tamura Y, Taniyama Y, Omata N, Tanaka Y, Moriya S, Furuya H, Kato M, Kawamura Y, Otowa T, Miyashita A, Kojima H, Saji H, Shimada M, Yamasaki M, Kobayashi T, Misawa R, Shigematsu Y, Kuwano R, Sasaki T, Ishigooka J, Wada Y, Tsuruta K, Chiba S, Tanaka F, Yamada N, Okawa M, Kuroda K, Kume K, Hirata K, Uchimura N, Shimizu T, Inoue Y, Honda Y, Mishima K, Honda M, Tokunaga K.

J Hum Genet. 2018 Dec;63(12):1259-1267. doi: 10.1038/s10038-018-0518-8. Epub 2018 Sep 28.

PMID:
30266950

Supplemental Content

Loading ...
Support Center